1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA,
et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients
with Atrial Fibrillation: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the
European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to Revise the 2001 Guidelines for the Management
of Patients With Atrial Fibrillation): developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm Society.
Circulation. 2006;114:e257-354.
2. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman
WM, et al. 2011 ACCF/AHA/HRS focused update on the management
of patients with atrial fibrillation (update on dabigatran): a report of the
American College of Cardiology Foundation/American Heart Association
Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330–7.
3. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman
JP, et al. Use of clopidogrel with or without aspirin in patients taking
oral anticoagulant therapy and undergoing percutaneous coronary
intervention: an open-label, randomised, controlled trial. Lancet.
2013;381:1107–15.
4. Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, et al. Use
of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After
Percutaneous Coronary Intervention. Ann Intern Med. 2017;167:17–25.
5. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting
stents. N Engl J Med. 2014;371:2155–66.
6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al.
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of
the American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am
Coll Cardiol. 2019;74:104–32.
7. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al.
2017 ESC focused update on dual antiplatelet therapy in coronary artery
disease developed in collaboration with EACTS: The Task Force for dual
antiplatelet therapy in coronary artery disease of the European Society
of Cardiology (ESC) and of the European Association for Cardio-Thoracic
Surgery (EACTS). Eur Heart J. 2018;39:213–60.
Kurimura et al. Journal of Pharmaceutical Health Care and Sciences
(2023) 9:28
8. Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al.
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in
Patients With Coronary Artery Disease. Circ J. 2020;84:831–65.
9. Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist
interventions on adult outpatients with cancer: A systematic review. J
Clin Pharm Ther. 2017;42:414–24.
10. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic
Review of Randomized Controlled Trials. J Manag Care Spec Pharm.
2016;22:493–515.
11. Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H. Reduced drug
use and hospitalization rates in patients undergoing hemodialysis who
received pharmaceutical care: a 2-year, randomized, controlled study.
Pharmacotherapy. 2009;29:1433–40.
12. Kurimura T, Yamamoto K, Ikeda T, Hashimoto M, Nishioka T, Kume M,
et al. Assessment of Pharmacist’s Intervention in the Prescription Process
in Pharmaceutical Outpatient Clinics. Jpn J Pharm Health Care Sci.
2017;43:169–75 (in Japanese).
13. Kurimura T, Omoto N, Kume M, Makimoto H, Hirano T, Hirai M. Practice
and Evaluation of Physical Assessment by Clinical Pharmacist in the
Cardiovascular Medicine Ward. J Jpn Soc Hosp Pharm. 2014;50:323–8 (in
Japanese).
14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al.
Standardized bleeding definitions for cardiovascular clinical trials: a
consensus report from the Bleeding Academic Research Consortium.
Circulation. 2011;123:2736–47.
15. Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, et al. JCS/JSCVS
2018 Guideline on Revascularization of Stable Coronary Artery Disease.
Circ J. 2022;86:477–588.
16. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist
C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial
fibrillation developed in collaboration with the European Association for
Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and
management of atrial fibrillation of the European Society of Cardiology
(ESC) Developed with the special contribution of the European Heart
Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
17. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381:1103–13.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest.
2010;138:1093–100.
19. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized
trials. Arch Intern Med. 2008;168:687–94.
20. Levenson SA, Saffel DA. The consultant pharmacist and the physician in
the nursing home: roles, relationships, and a recipe for success. J Am Med
Dir Assoc. 2007;8:55–64.
21. Denneboom W, Dautzenberg MG, Grol R, De Smet PA. Treatment reviews
of older people on polypharmacy in primary care: cluster controlled trial
comparing two approaches. Br J Gen Pract. 2007;57:723–31.
22. Okada H, Onda M, Shoji M, Sakane N, Nakagawa Y, Sozu T, et al. Effects of
lifestyle advice provided by pharmacists on blood pressure: The COMmunity Pharmacists ASSist for Blood Pressure (COMPASS-BP) randomized
trial. Biosci Trends. 2018;11:632–9.
23. Awker AL, Bell MA, McGraw M, Klein MA. Impact of educational intervention on management of periprocedural anticoagulation. Am J Health Syst
Pharm. 2017;74:S95-s101.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Page 10 of 10
Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
...
論文の公開元へ
